Boston Scientific’s offer not as sweet as it seems:
BEHIND THE NEWS Boston Scientific’s offer not as sweet as it seems Now that Guidant Corp. has agreed to be acquired by Boston Scientific Corp. for $27 billion, or $80 a share, investors in the Indianapolis company can rest easy, right? Not really, a close reading of the medical-device companies’ merger agreement shows. It turns out Guidant shareholders are entitled to $80 a share in cash and stock only if the average closing price of Boston Scientific’s stock in the…